Drug
Obeticholic acid clinical trials
Also written INT-747 and Ocaliva.
Keep track of what changes. Save the obeticholic acid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 15
Intercept Pharmaceuticals (16) · GlaxoSmithKline (2) · Sahlgrenska University Hospital (2) · National Cancer Institute (NCI) (2) · Tanta University (1) · King Edward Medical University (1) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1) · Abhimanyu Garg (1)
Often tested with
Tested in the same studies.
Bezafibrate (2) · Linerixibat (2) · Vitamin E (1) · Ursodeoxycholic Acid (1)
Studies
Open first, then newest update. How each study uses obeticholic acid is read from its arms, and is right about nine times in ten.
Testing it · 35
- Obeticholic Acid for Prevention in Barrett's EsophagusRecruitingPhase 2National Cancer Institute (NCI)NCT04939051Written as Obeticholic Acid
- Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler OutcomesNot yet recruitingPhase 3Assiut UniversityNCT06691412Written as Obeticholic Acid 5 mg
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCCompletedPhase 2Intercept PharmaceuticalsNCT05239468Written as Obeticholic Acid 5 mg
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBCTerminatedPhase 2Intercept PharmaceuticalsNCT04594694Written as Obeticholic acid
- Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyTerminatedPhase 2/3Intercept PharmaceuticalsNCT06121375Written as OCA
- Testing Obeticholic Acid for Familial Adenomatous PolyposisTerminatedPhase 2National Cancer Institute (NCI)NCT05223036Written as Obeticholic Acid
- Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver DiseaseCompletedPhase 2King Edward Medical UniversityNCT07104786Written as Obeticholic Acid 10 MG
- Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic SteatohepatitisActive, not recruitingPhase 2Tanta UniversityNCT05573204Written as Obeticholic Acid Oral Tablet
- Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary CirrhosisCompletedPhase 3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06715319Written as OCA
- Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentTerminatedPhase 3Intercept PharmaceuticalsNCT02548351Written as Obeticholic Acid
- Phase 2 Study of Obeticholic Acid for Lipodystrophy PatientsCompletedPhase 2Abhimanyu GargNCT02430077Written as Obeticholic Acid
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)TerminatedPhase 2Intercept PharmaceuticalsNCT00550862Written as INT-747
- Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompletedPhase 3Intercept PharmaceuticalsNCT03439254Written as Obeticholic acid (10 mg)
- Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) SignalingCompletedNot applicableSuthat LiangpunsakulNCT02654236Written as 10 mg Obeticholic Acid (OCA)
- Obeticholic Acid in Bile Acid DiarrhoeaCompletedPhase 2Imperial College Healthcare NHS TrustNCT01585025Written as Obeticholic acid
- Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary CholangitisTerminatedPhase 4Intercept PharmaceuticalsNCT02308111Written as Obeticholic Acid (OCA)
- The Effect of Obeticholic Acid in Healthy VolunteersStatus unknownNot applicableUniversitaire Ziekenhuizen KU LeuvenNCT05740631Written as Ocaliva
- Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult ParticipantsCompletedPhase 1GlaxoSmithKlineNCT05133830Written as Obeticholic acid
- Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic ImpairmentTerminatedPhase 4Intercept PharmaceuticalsNCT03633227Written as Obeticholic Acid (OCA)
- Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary CirrhosisCompletedPhase 2Intercept PharmaceuticalsNCT01865812Written as Obeticholic Acid
See all 35 studies that test obeticholic acid →
Given in every arm · 1 — obeticholic acid is usual care beside what is tested
Codes
What other systems call obeticholic acid · ClinicalTrials.gg INT004470
- MeSH (NLM) C464660obeticholic acidConfirmed NLM, Wikidata
- UNII (FDA) 0462Z4S4OZOBETICHOLIC ACIDConfirmed FDA, NLM, Wikidata
- RxNorm 1798288Confirmed FDA, Wikidata
- Wikidata Q15708271obeticholic acidConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80837Obeticholic AcidOne source FDA
- DrugBank DB05990One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C464660 | obeticholic acid | Confirmed NLM, Wikidata |
| UNII (FDA) | 0462Z4S4OZ | OBETICHOLIC ACID | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1798288 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708271 | obeticholic acid | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80837 | Obeticholic Acid | One source FDA |
| DrugBank | DB05990 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.